We conclude that NSCLC slices of both KL and KP genotypes, and regardless of AC or ASC pathology, show a lack of sensitivity to single pathway inhibition, but show selective sensitivity to combination treatment with MAPK and PI3K–mTOR inhibitors. Here, MTOR is linked to non-small cell lung carcinoma.